Alumis (ALMS) Free Cash Flow (2023 - 2025)
Alumis (ALMS) posted quarterly Free Cash Flow of -$76.8 million for Q4 2025, down 2.18% year-over-year from -$78.5 million in Q4 2024, and up 30.79% quarter-over-quarter from -$110.9 million in Q3 2025.
Alumis (ALMS) Free Cash Flow (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Free Cash Flow for 3 consecutive years, with -$76.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow fell 2.18% year-over-year to -$76.8 million; the TTM figure through Dec 2025 stood at -$375.0 million (down 46.04% YoY), while the FY2025 annual figure was -$375.0 million, down 46.04% from the prior year.
- Free Cash Flow grew to -$76.8 million in Q4 2025 per ALMS's latest filing, from -$110.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$35.0 million in Q4 2023 and bottomed at -$110.9 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$70.2 million across 3 years, with a median of -$75.9 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 139.05% — and 2025, when it decreased 2.18%.
- Alumis' Free Cash Flow stood at -$35.0 million in 2023, then plunged by 114.6% to -$75.1 million in 2024, then retreated by 2.18% to -$76.8 million in 2025.
- Business Quant data shows ALMS's Free Cash Flow at -$76.8 million in Q4 2025, -$110.9 million in Q3 2025, and -$106.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -76.77 Mn |
| Dec 31, 2025 | -76.77 Mn |
| Sep 30, 2025 | -110.92 Mn |
| Sep 30, 2025 | -110.92 Mn |
| Jun 30, 2025 | -106.92 Mn |
| Jun 30, 2025 | -106.92 Mn |
| Mar 31, 2025 | -80.44 Mn |
| Mar 31, 2025 | -80.44 Mn |
| Dec 31, 2024 | -75.13 Mn |
| Dec 31, 2024 | -75.13 Mn |
| Sep 30, 2024 | -84.55 Mn |
| Sep 30, 2024 | -84.55 Mn |
| Jun 30, 2024 | -52.68 Mn |
| Jun 30, 2024 | -52.68 Mn |
| Mar 31, 2024 | -44.46 Mn |
| Mar 31, 2024 | -44.46 Mn |
| Dec 31, 2023 | -35.01 Mn |
| Dec 31, 2023 | -35.01 Mn |
| Sep 30, 2023 | -35.37 Mn |
| Sep 30, 2023 | -35.37 Mn |